What question did this study set out to answer?

To evaluate the efficacy and safety of recombinant human thrombopoietin (rhTPO) for improving outcomes in septic ICU patients with severe thrombocytopenia.

March 26, 2026Critical Care Medicine

836: Multicenter RCT of Recombinant Human Thrombopoietin for Icu Sepsis With Severe Thrombocytopenia

View Full Paper

Ask AI

Bookmark

Authors

ZZZixuan ZhouBeijing Institute of Technology YXYun XieOspedale San Bortolo RWRuilan Wang

Discussion

Member takes

Implication

Multicenter RCT examines rhTPO's impact on mortality in ICU patients with severe thrombocytopenia, suggesting targeted benefits in certain subgroups.

Key Points

To evaluate the efficacy and safety of recombinant human thrombopoietin (rhTPO) for improving outcomes in septic ICU patients with severe thrombocytopenia.
Conducted a multicenter, open-label randomized controlled trial (RCT)
Enrolled 204 septic patients with severe thrombocytopenia across 8 ICUs in China
Administered rhTPO 15,000 U/day for 7 days to one group and placebo to another
Assessed primary endpoint of 28-day all-cause mortality and various secondary endpoints
28-day mortality was 17.3% in the rhTPO group versus 24.4% in the placebo group, not statistically significant
Significant reduction in mortality observed in patients under 65 with specific health criteria
rhTPO showed an upward trend in platelet counts, with faster recovery in younger patients
Safety profile comparable between groups, with no increase in bleeding or thromboembolism risks

Cite This Study

Zhou et al. (2026) studied this question.

synapsesocial.com/papers/69c4cda5fdc3bde44891a4e7 https://doi.org/10.1097/01.ccm.0001185340.65899.43

View Full Paper

Ask AI

Bookmark

Implication

Multicenter RCT examines rhTPO's impact on mortality in ICU patients with severe thrombocytopenia, suggesting targeted benefits in certain subgroups.

836: Multicenter RCT of Recombinant Human Thrombopoietin for Icu Sepsis With Severe Thrombocytopenia

Discussion

Member takes

Implication

Key Points

Cite This Study

836: Multicenter RCT of Recombinant Human Thrombopoietin for Icu Sepsis With Severe Thrombocytopenia

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider